FDA Approves First MSC Therapy for SR-aGVHD: A Milestone in Cell Therapy
The U.S. Food and Drug Administration (FDA) has announced the historic approval of Ryoncil (remestemcel-L-rknd) as the first mesenchymal stromal […]
Launch of DestroCell in Tehran Marks a New Era in Cell Therapy for Iran and Beyond
On Thursday morning, October 24, 2024, doctors, researchers, and other distinguished guests gathered at Tehran’s Spinas Palace Hotel for the
DestroCell Offers New Hope for Steroid-Resistant GVHD Treatment
Tehran, Iran – September 13, 2024 — In a significant breakthrough for cell therapy and regenerative medicine, Taskin Bioregeneration Co.